Robert J Kreitman
Overview
Explore the profile of Robert J Kreitman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
4978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arons E, Tai C, Suraj J, Liu Y, Day C, Raffeld M, et al.
Blood
. 2024 Dec;
PMID: 39719040
We found 18 patients with immunophenotype consistent with classic hairy cell leukemia (HCL) and BRAF mutations other than just V600E. Twelve had 1 non-V600E BRAF mutation and 6 had V600E...
2.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, et al.
Leukemia
. 2024 Jun;
38(7):1642-1644.
PMID: 38851853
No abstract available.
3.
Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al.
EClinicalMedicine
. 2023 Nov;
65:102307.
PMID: 38033506
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed...
4.
Arons E, Henry K, Haas C, Gould M, Tsintolas J, Mauter J, et al.
J Med Virol
. 2023 Oct;
95(10):e29179.
PMID: 37877800
Although monoclonal antibodies to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are known, B-cell receptor repertoire and its change in patients during coronavirus disease-2019 (COVID-19) progression is underreported. We aimed...
5.
Kreitman R, Yu T, James L, Feurtado J, Eager H, Ortiz O, et al.
Blood Adv
. 2023 Sep;
7(23):7161-7168.
PMID: 37729613
Hairy cell leukemia (HCL), similar to its variant HCLv, is a B-cell malignancy associated with decreased humoral immunity. We prospectively monitored the largest cohort of patients with HCL/HCLv to date...
6.
Subbiah V, Kreitman R, Wainberg Z, Gazzah A, Lassen U, Stein A, et al.
Nat Med
. 2023 Apr;
29(5):1103-1112.
PMID: 37059834
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor)...
7.
Chihara D, Gras L, Zinger N, Kroger N, Mayer J, Passweg J, et al.
Haematologica
. 2022 Dec;
108(6):1676-1679.
PMID: 36546416
No abstract available.
8.
Ravandi F, Kreitman R, Tiacci E, Andritsos L, Banerji V, Barrientos J, et al.
Blood Cancer J
. 2022 Dec;
12(12):165.
PMID: 36509740
A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell...
9.
Kreitman R, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet A, et al.
Blood
. 2022 Sep;
141(9):996-1006.
PMID: 36108341
BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive...
10.
Andritsos L, Anghelina M, Neal J, Blachly J, Mathur P, Lele O, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3021-3031.
PMID: 36070610
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder, comprising only 2% of all leukemias. The Hairy Cell Leukemia Foundation (HCLF) has developed a patient data registry to enable investigators...